This cell line has been engineered to enable tetracycline inducible expression of the kinase MRCK?. MRCK? is a myotonic dystrophy kinase-related CDC42-binding kinase involved in regulating actin-myosin contractility and implicated in cancer metastasis. MRCK?, in conjunction with MRCKa, ROCK1 and ROCK2 kinases, initiates signalling events that lead to contractile force generation which powers cancer cell motility and invasion.
| Inventor | Institute |
|---|---|
| Daniel Croft ; Justin Bower ; Heather Mckinnon | Cancer Research UK, Glasgow: The Beatson Institute |
| SKU: | 154149 |
|---|---|
| Product description: | This cell line has been engineered to enable tetracycline inducible expression of the kinase MRCK?. MRCK? is a myotonic dystrophy kinase-related CDC42-binding kinase involved in regulating actin-myosin contractility and implicated in cancer metastasis. MRCK?, in conjunction with MRCKa, ROCK1 and ROCK2 kinases, initiates signalling events that lead to contractile force generation which powers cancer cell motility and invasion. The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Useful for the study of breast cancer cell cytoskeleton reorganisation and cell migration. This cell line is derived from a triple negative breast cancer (TNBC) meaning it does not express oestrogen, progesterone or HER2 receptors. Treatment with doxycycline induced MRCKÄÂ? kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be ‘leaky’ in any clones tested. |
| Alternate name: | Serine/threonine-protein kinase MRCK beta, CDC42-binding protein kinase beta, CDC42BP-beta, DMPK-like beta, Myotonic dystrophy kinase-related CDC42-binding kinase beta, MRCK beta, Myotonic dystrophy protein kinase-like beta |
| Conditional: | Yes |
| Conditional description: | MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G regulated expression of MRCKÄÂ?Â. Therefore MRCKÄÂ? expression is induced in the presence of doxycycline. |
| Additional notes: | Treatment with doxycycline induced MRCK? kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be ‘leaky’ in any clones tested. Tet-On System owned by TET Systems GmbH & Co. KG. |
| Parental cell line: | MDA-MB-231 D3H2LN-Luc cell line |
| Disease: | Cancer |
| Cat. #: | 154149 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Organism: | Human |
| Tissue: | Breast |
| Model: | Transgenic |
| Growth properties: | Adherent cell line. Membrane blebbing/cytoskeleton reorganisation and migration induced in the presence of doxycycline. |
| Cancer Types In Detail: | Triple negative breast (TNBC) |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | 10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine |
| Recommended controls: | MDA-MB-231 D3H2LN-Luc parental line |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Unbekandt et al. 2014. Cell Commun Signal. 12:54. PMID: 25288205. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.